Alexion deal lends late-stage support to Stealth

Alexion continued its run of deals by obtaining an option to a Phase III candidate from Stealth, which would get a boost in building its commercial infrastructure ahead of a regulatory submission next year and be able to devote more resources to its earlier stage programs.

Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) will receive an option to license exclusive ex-U.S. rights as well as rights to co-promote and develop subcutaneous elamipretide in the U.S. The company can opt in after data is reported from the Phase III trial in primary mitochondrial myopathy, which is expected in January. Stealth said an NDA submission to FDA is tentative for 3Q20...